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Background: Cyclin D1 and its kinase partners control cell cycle progression. Cyclin D1 is frequently deregulated in
various cancers, including malignant hemopathies, and tumor cells display uncontrolled cell proliferation. Cyclin D1
is not expressed in the B-cell lineage but is found in multiple myeloma (MM) cells in almost 50% of patients with
this condition. Paradoxically, cyclin D1 expression is associated with a good prognosis and longer overall survival in
MM patients.
Methods: We used two independent MM cell lines (RPMI 8226 and LP1) to generate several clones stably expressing
either the green fluorescent protein (GFP) or a GFP-cyclin D1 fusion protein, and we analyzed the properties acquired
following cyclin D1 expression.
Results: Whole-genome expression analysis in the cell clones indicated that cyclin D1 profoundly modified several
cellular functions, including the regulation of apoptotic cell death. We studied the apoptotic response of GFP- and
GFP-cyclin D1-expressing clones to bortezomib-treatment. We found that the apoptotic response occurred faster
and was of a greater amplitude in cyclin D1-expressing cells. Cyclin D1 expression enhanced the caspase-dependent
apoptosis mediated by the intrinsic mitochondrial pathway. More importantly, cyclin D1 also activated the unfolded
protein response (UPR) and induced endoplasmic reticulum (ER) stress-mediated apoptosis.
Conclusion: The ER is well known to be a crucial regulator of plasma cell death and it plays the same role in their
malignant counterparts, myeloma cells. This role involves activation of the UPR controlled at least in part by cyclin D1.
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Caspase-dependent apoptosisBackground
The CCND1 gene encoding cyclin D1 is the second most
frequently amplified locus in solid cancers [1]. Moreover,
cyclin D1 is overexpressed in human cancers, including
malignant hemopathies, after genetic alterations, such as
chromosomal translocation, but also in the absence of
any detectable genetic alteration [2]. Tumor cells with
high cyclin D1 levels have higher proliferation rate and
lower nutrient requirements that tumor cells that do not
express cyclin D1. This is consistent with the well known
function of cyclin D1 in cell cycle regulation through
cyclin-dependent kinase 4/6 activation [3]. However, the* Correspondence: brigitte.sola@unicaen.fr
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increase in proliferation. Indeed, depending on its subcellu-
lar distribution (nuclear, cytoplasmic, at the outer mito-
chondrial membrane) and partners (transcription factors,
chromatin-modifying enzymes, cytosolic proteins), cyclin
D1 can regulate transcriptional regulation [4], DNA
damage response [5,6], centrosome duplication [7],
chromosomal instability [8], senescence [9], mitochon-
drial function [10] and migration [11-13]. All these pro-
cesses, if left uncontrolled, can initiate or/and maintain
transformation processes.
In 15% of patients with multiple myeloma (MM), a
hematological disease characterized by the accumula-
tion of malignant plasma cells in the bone marrow, cyc-
lin D1 is aberrantly expressed as a result of the t(11;14)l. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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lin D1 expression is detected in 40% of MM cases, most
displaying hyperdiploidy [15]. Consistent with its role
in cell cycle regulation, cyclin D1 has been shown to
regulate MM cell proliferation [16]. Paradoxically, MM
patients with cyclin D1-expressing tumor cells have a
good prognosis and a longer overall survival [17]. The
possibility of additional functions for cyclin D1 in MM
cells is key issue that has been little addressed. We
investigated this possibility, by generating stable MM
cell line-derived clones expressing a cyclin D1-green
fluorescent protein (GFP) fusion protein (D1-GFP) or
GFP alone. We used arrays to investigate gene expres-
sion in D1-GFP- and GFP-expressing cells. We found
that the presence of cyclin D1 altered the expression of
genes involved in metabolism, membrane trafficking,
adhesion/migration, cell proliferation, inflammation,
and cell death/apoptosis. We also found that cyclin D1
expression was sufficient to sensitize MM cells to the
induction of apoptosis by bortezomib. This greater
sensitivity of cyclin D1-expressing cells was mediated
by the activation of the unfolded protein response
(UPR) pathway and endoplasmic reticulum (ER)-stress
signaling, triggering apoptosis. Our data reveal a novel
molecular mechanism by which cyclin D1 expression
directly targets the UPR, enhancing the response to
bortezomib in MM tumor cells, as highlighting by clin-
ical observations.Methods
Chemicals
Bortezomib and Z-LEVD [Z-LE(OMe)VD(OMe)-FMK],
a caspase 4 inhibitor, were purchased from Euromedex.
Q-VD-OPh [quinoyl-valyl-O-methylaspartyl-(2,6-difluoro-
phenoxy)-methyl ketone], a pancaspase inhibitor, was
purchased from Sigma-Aldrich. Q-VD-OPh and Z-LEVD
were dissolved in dimethyl-sulfoxide (DMSO) (Sigma-
Aldrich) and bortezomib was dissolved in 0.9% NaCl.
For controls, vehicle (DMSO or NaCl) was added at the
same final concentration.Generation of cyclin D1-expressing cell lines
RPMI 8226 cells (referred to here as 8226 cells) were
purchased from DSMZ (ACC-402). LP1 cells were
generously provided by R Bataille (Centre de recherche
en cancérologie Nantes-Angers, Nantes, France). U266
(ACC-9) and KMS-12-PE (ACC-606), from DSMZ,
were used as positive control for cyclin D1 expression
in immunocytochemistry analysis. Human myeloma
cell lines (HMCLs) were maintained in RPMI 1640
medium (Lonza) supplemented with 2 mM L-glutamine
(Lonza), 10% fetal calf serum (FCS, PAA Laboratories)
and antibiotics (Lonza).The pEGFP-N1 plasmid was purchased from Clontech
Laboratories Inc. and the p-cyclin D1-EGFP plasmid was
kindly provided by D. Salomon (USCF School of Medicine,
San Francisco, CA, USA). This plasmid was sequenced
to check the integrity of the coding sequence, amplified
and purified with the QIAGEN maxi kit (Qiagen). We
electroporated (250 V, 950 μF, Gene Pulser II, Bio Rad)
107 8226 or LP1 cells with 10 μg pEGF-N1 or p-cyclin
D1-EGFP plasmids in RPMI 1640 medium without FCS.
After incubation for 24 h, the cells were transferred
to complete medium supplemented with 500 μg/mL G418
(PAA Laboratories). They were cloned by limiting dilution
methods. Clones were maintained under selective pressure
and selected on the basis of their FL1-fluorescence by
flow cytometry (Gallios, Beckman Coulter). Data were
analyzed with the Kaluza software (Beckman Coulter).
Cell viability measurement
Cell proliferation was determined by directly counting
the cells after trypan blue staining. Cell viability was
quantified with the CellTiter 96® AQueous One Solution
(MTT [(3-(4,5)-dimethylthiazol-2-yl)-2,5-diphenyltetrazo-
lium bromide] assay (Promega), according to the manufac-
turer’s instructions.
Apoptosis determination by APO2.7 staining and
cytometry sorting
Drug-exposed HCMLs and control cells were stained
with the APO2.7-PE-conjugated antibody (Ab), as de-
scribed by the manufacturer (Beckman Coulter), and
analyzed by flow cytometry. We analyzed at least 104
cells for each set of culture conditions, and each experi-
ment was carried out three times.
Indirect immunofluorescence and confocal microscopy
analysis
Cells (2 × 105 per spot) were cytopsun on Superfrost
slides at 500 g for 3 min, then fixed in 4% paraformalde-
hyde for 15 min and permeabilized with 0.5% Triton
X100 for 5 min. Slides were processed as previously de-
scribed [10], with an anti-cyclin D1 (sc-718, Santa Cruz
Biotech., Santa Cruz CA) as primary Ab and AlexaFluor
633-labeled anti-rabbit IgG (Molecular Probes) as second-
ary Ab. Nuclei were counterstained with 4′,6-diamidino-2-
phenylindole, dihydrochloride (DAPI). Slides were analyzed
with a Fluoview FV1000 confocal microscope and Fluoview
Viewer software (Olympus).
Western blotting
Whole-cell lysates were obtained with M-PER® Mam-
malian Protein Extraction Reagent (Thermo Scientific,
Rockford, Illinois, USA), and western blotting was car-
ried out as described elsewhere [18]. We used primary
Abs against poly(ADP-ribosyl)transferase (or PARP, #9542),
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(p)-eIF2α (#9721), and BiP (#3183) from Cell Signaling
Tech. (Danvers, MA). The Abs against MCL1 (S-19);
caspase 3 (H-277), caspase 8 (H-134), cyclin D1 (M-
20), cyclin D2 (M-20), XBP1 (M-186), and β-actin (C4)
were obtained from Santa Cruz Biotech. The Ab against
GAPDH (clone 6C5) was obtained from Life Technolo-
gies; that against caspase 4 (M029-3) was obtained from
MBL and the Ab against BCL2 (M0887) was obtained from
Dako. The secondary Abs used were goat anti-rabbit or
anti-mouse peroxidase-conjugated IgGs (Abcam).
RNA extraction, quantification, amplification and real-time
polymerase chain reaction
RNA was extracted with the RNAeasy® Mini kit
(Qiagen), according to the manufacturer’s instructions,
and quantified with a Smartspec™ 3000 spectrometer
(Bio-Rad). We generated cDNAs from 2 μg of RNA with
M-MuLV-reverse transcriptase, according to the manu-
facturer’s instructions (Invitrogen, Life Technologies).
The cDNA was then subjected to real-time PCR with
the SYBR Green system (Applied Biosystems, Life Tech-
nologies) and primers for RPLP0, GAPDH, CXCR3,
BTBD3, MCL1, BCL2L1, RND3 and CXCL10 (Additional
file 1). BiP, GRP94 and CHOP cDNAs were amplified as
previously described [19]. We used the StepOnePlus
real-time PCR System (Applied Biosystems). Data were
analyzed with Step One software V2.2.2 (Applied Bio-
systems). Gene expression was quantified by the ΔΔCt
method, with RPLP0 used as the internal standard. The
fold change in expression (Fc) was calculated as 2-ΔΔCt.
Whole-genome expression analysis
Total RNA was purified from four independent cultures
of 8226 GFP (Cl1), RPMI 8226 D1-GFP (Cl2), LP1 GFP
(Cl4) and LP1 D1-GFP (Cl3) cells, with the RNAeasy®
Mini kit (Qiagen). RNA was quantified with a Nanodrop
ND-1000 spectrophotometer (Thermo Fisher Scientific
Inc.). RNA integrity was assessed with a Bioanalyzer 2100
machine and the RNA6000 Nano kit (Agilent Technologies
Inc.). All samples had a RNA integrity number of at least
7.00. No signs of DNA contamination were detected. We
used 400 ng of total RNA per sample. We used the Illumina
Total Prep RNA Amplification Kit (Ambion, Life Technolo-
gies) to generate biotinylated, amplified cRNA, according to
the manufacturer’s recommendations. Hybridization on
Illumina HumanHT-12 v4 Expression BeadChips, and the
staining and detection of cRNAs with the I-Scan system
were performed according to the manufacturer’s rec-
ommendations (Illumina Inc., San Diego, USA). The
HumanHT-12 v4 Expression BeadChip assesses a total
of 47,231 marker probes, 28,688 of which are NM cod-
ing transcripts; and 11,121 are XM coding transcripts
(RefSeq Content, Build 33.1, Release 5). It also contains3,461 experimentally confirmed mRNA sequences that
have been aligned with EST clusters. GenomeStudio
2011.1 software (Illumina Inc.) and its Gene Expression
Analysis Module (version 1.9.0) were used for signal ex-
traction and quantile normalization. Processed probe
data were then filtered according to the following cri-
teria: minimal signal intensity fold-change of 1.50 across
all samples; minimal absolute change in probe signal in-
tensity of 150 across all samples, based on the variance
of gene expression, with a 10% threshold. The filtered
data were then log-transformed and exported to appro-
priate software for secondary analyses. Omics Explorer
2.2 software (Qlucore, Lund, Sweden [20]) was used for
hierarchical clustering and analyses of differential ex-
pression. An adjusted p-value (q-value) of 0.01 was con-
sidered as significant in the differential expression
analyses. The primary probe data were subjected to
quantile normalization. Genes were considered to be
differentially expressed if the absolute fold-change (Fc)
in mean expression values between D1-GFP-expressing
cells and GFP-expressing cells was at least 1.5.
Statistical analysis
Student’s t-test was used to determine the significance of
differences between two experimental groups. Data were
analyzed in two-tailed tests, with p < 0.05 (*) considered
significant and p < 0.01 (**) considered highly significant.
Results
Cyclin D1 is expressed and functional in 8226- and
LP1-derived clones
We investigated the role of cyclin D1, in two HMCLs (8226
and LP1 cells), from molecular groups of MM with a poor
prognosis [17,21], in which cyclin D1 protein was barely de-
tected. Cells were transfected by electroporation with plas-
mids encoding GFP or D1-GFP and were selected for
neomycin resistance. Clones for each HMCL were obtained
by limiting dilution cloning and their protein levels were
quantified by flow cytometry (Additional file 2). The GFP-
expressing clones obtained from the two parental cell lines
were highly fluorescent, suggesting that the electroporation
conditions were optimal (Figure 1A). However, D1-GFP
protein levels were only moderate in 8226 cells and low in
LP1 cells. The presence of the D1-GFP fusion protein in
these clones was confirmed by immunoblotting with an
anti-cyclin D1 Ab (Figure 1B). Consistent with previous ob-
servations [16], an upregulation of cyclin D1 correlated
with a downregulation of cyclin D2 (Figure 1B). According
to other reports [22-24], high levels of cyclin D1 are dele-
terious for MM cell survival, and only clones with moder-
ate or low cyclin D1 levels survive. Like cyclin D1, the
GFP-cyclin D1 fusion protein was present in both the nu-
cleus and cytoplasmic compartments (Figure 1C). We
then compared the proliferation properties of D1-GFP-
Figure 1 Cyclin D1 is expressed in 8226- and LP1-derived clones. A. The GFP fluorescence (FL1) of parental cells and the clones derived from
them were analyzed by flow cytometry. Representative profiles are shown from the selected clones: in black, parental cells; light gray: cyclin
D1-GFP clone; dark gray: GFP clone. B. Whole-cell proteins extracts were obtained from GFP- and cyclin D1-GFP-expressing cells, and subjected to
SDS-PAGE and immunoblotting with the indicated Abs. An Ab directed against β-actin was used as loading control. The 8826 D1-GFP Cl2 and
LP1 D1-GFP Cl3 clones were used for the experiments shown in parts A and D of this figure and for subsequent investigations. C. 8226 cells
expressing exogenous cyclin D1 or U266 and KMS-12-PE cells expressing endogenous cyclin D1 were stained with anti-cyclin D1 Ab then with
AlexaFluor 633-conjugated anti-mouse IgG (in green) and couterstained with DAPI (in blue). Slides were analyzed by confocal microscopy (Fluoview
microscope). D. Clones presented in A were used to seed complete medium at a density of 2 × 105 cells/ml, and their growth was evaluated daily, over
a three- or four-day period, by direct counting after trypan blue staining. The experiment was carried out three times in triplicate. The mean number of
living cells is shown, together with the SD. *p < 0.05; **p < 0.01 in Student’s t-test.
Bustany et al. BMC Cancer  (2015) 15:262 Page 4 of 12and GFP-expressing clones. As expected, clones express-
ing cyclin D1 displayed high levels of cell proliferation
(Figure 1D). Our data demonstrated that, despite its low
level of expression, cyclin D1 affects HMCL behavior.
Cyclin D1 expression alters various cellular processes
including cell death/apoptosis
We selected one clone from each 8226 and LP1 series for
gene expression analysis. For each clone (8226 GFP Cl1,
8226 D1-GFP Cl2, LP1 GFP Cl4, LP1 D1-GFP Cl3), total
RNA was purified from four independent cultures and usedfor whole-genome transcription profiling. The microarray
data and annotations have been deposited in the NCBI/
NIH Gene Expression Omnibus (GEO) under the accession
number [GSE59673]. As illustrated by the heatmaps
obtained, cyclin D1 had a significant impact on gene
transcription in both cell lines (Figure 2A). Real-time
RT-PCR was performed to validate the microarray re-
sults. Microarray and RT-PCR data were particularly
well correlated for seven genes differentially regulated
between the GFP-D1 series and GFP series (regardless of
whether expression was upregulated or downregulated in
Figure 2 Cyclin D1 expression in HCMLs alters various molecular functions. A. The whole-genome expression patterns for 8226 D1-GFP vs. 8226
GFP (left) and LP1 D1-GFP vs. LP1 GFP (right) are shown as heat maps. Each column represents a sample; each row represents a marker (gene
transcript). The log2 relative gene expression scale is shown at the bottom left. The differentially expressed genes (Fc threshold≥ 1.5, q = 0.01)
were classified as cyclin D1-activated genes (in red) or cyclin D1-inhibited genes (in green). B. Real-time quantitative RT-PCR for the validation of
microarray data. The sequences of the primers used for RT-PCR are indicated in the Additional file 1. For each sample, the mean Ct value for the
internal standard (RPLP0) was subtracted from the mean Ct value for each gene, to obtain the ΔΔCt. The formula N = 2-ΔΔCt was used to calculate
the Fc in expression. The experiments were carried out three times; mean ± SD values are indicated in the table. For each gene, the Fc calculated
from microarray data is indicated in the column on the right. C. Genes for which expression levels were altered (Fc > 2) by cyclin D1 expression
were ordered by function-related groups, for both cell lines. The number of genes with altered expression levels corresponding to each cell
function is indicated on the graph.
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expressed genes were then subjected to hierarchical
clustering on the basis of their biological functions,
with DAVID Bioinformatics Resources 6.7 [25]. Many
genes involved in DNA synthesis/cell proliferation, cell
cycle regulation, or adhesion/migration were character-
ized (Figure 2C); cyclin D1 has well known roles in
these functions [4-13]. Moreover, we found, in both cell
models, changes in transcription levels for genes involved
in metabolism, protein synthesis, membrane trafficking,
lymphocyte stimulation, inflammation and cell death/
apoptosis, functions not previously associated with cyclin
D1. We then carried out a functional enrichment analysisfor the differentially expressed genes with DAVID, focusing
on genes displaying a Fc in expression > 2. Four (for 8226
cells) and five (for LP1 cells) gene ontology clusters were
identified including two clusters common to both series:
inflammatory response and cell death/apoptosis (Table 1).
We then focused on the role of cyclin D1 in regulating
apoptosis.
Cyclin D1 sensitizes HMCLs to bortezomib by increasing
caspase-dependent apoptosis driven by the intrinsic
pathway
Cyclin D1 has been reported to play a direct role in the regu-
lation of apoptosis and, thus, in the resistance/sensitization
Table 1 Enrichment of differentially expressed genes in Gene Ontology terms
Cluster Gene ontology term Enrichment score No. of genes Total genes % of genes
Clusters for RPMI D1-GFP vs. GFP
1 Inflammatory response 5.03 27 108 25.00
2 Extracellular matrix binding 3.45 9 116 7.76
3 Extracellular space 2.66 29 129 22.48
4 Cell death/apoptosis 1.93 13 108 12.04
Clusters for LP1 D1-GFP vs. GFP
1 Antigen processing 5.58 7 48 14.58
2 Inflammatory response 2.05 5 48 10.42
3 Bone development 0.96 3 48 6.25
4 Developmental process 0.88 17 48 35.42
5 Cell death/apoptosis 0.72 4 48 8.33
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the differentiation state of cells of the B-cell lineage, cyclin
D1 may have anti-apoptotic effects [26,27] or may increase
chemosensitivity [28]. We investigated the effects of cyclin
D1 on the apoptotic response, by treating clones expressing
GFP or D1-GFP with bortezomib, a proteasome inhibitor
widely used to treat MM and B-cell hemopathies [29]. Cell
viability was assessed in a MTTassay. We first checked that
the GFP-expressing cells and the corresponding parental
cells had similar sensitivity (data not shown). The expres-
sion of cyclin D1 was associated with significantly lower
levels of cell viability after bortezomib-treatment in both
HMCLs (Figure 3A). Thus, cyclin D1 expression amplified
the response of HMCLs to bortezomib.
One clone from each series (8226 D1-GFP Cl1, 8226
D1-GFP Cl2, LP1 GFP Cl4, LP1 D1-GFP Cl3) was studied
further. These clones were stained with APO2.7-PE Ab
and sorted by FACS for the quantification of apoptosis.
The percentage of apoptotic cells (APO2.7-positive) after
bortezomib-treatment was higher for 8226- and LP1-D1-
GFP cells than for GFP-expressing clones (Figure 3B and
Additional file 3). Treatment of the 8226 and LP1 clones
with the Q-VD-OPh pancaspase inhibitor before bortezo-
mib treatment abolished the difference in response between
GFP- and D1-GFP-expressing clones (Figure 3C). These
findings confirmed that cyclin D1 potentiated caspase-
dependent apoptosis in HMCLs.
Caspase-dependent apoptosis is a well defined type of
programmed cell death controlled by an extrinsic path-
way after death receptor activation and/or by an intrinsic
pathway regulated by proteins of the B-cell lymphoma 2
(BCL2) family. Bortezomib induces caspase 8- and 9-
dependent apoptosis [30]. The treatment of 8226 D1-
GFP cells with bortezomib was sufficient to induce the
cleavage of procaspases 8, 9 and 3 (illustrated by the dis-
appearance of procaspase forms and the appearance of
active shorter forms) and, in turn, the cleavage of PARP
(Figure 3D). No such cleavage events were observed in8226 GFP cells. Similar results were obtained for
bortezomib-treated LP1 cells (Figure 3D). Apoptosis was
triggered in both GFP- and D1-GFP-expressing cells, but
cyclin D1 amplified the response.
The anti-apoptotic BCL2 and myeloid leukemia cell
differentiation 1 (MCL1) proteins are key regulators of
apoptosis in MM. MCL1, in particular, is essential for
the survival of plasma cells and its degradation is re-
quired for MM cell death [31]. Bortezomib treatment
decreased BCL2 and MCL1 levels in a dose-dependent
manner in both D1-GFP- and GFP-expressing clones,
but this effect was stronger in cyclin D1-expressing cells
(Figure 3E). We concluded that the higher chemosensi-
tivity of D1-GFP-expressing clones resulted from early
procaspase activation and triggering of the intrinsic
apoptotic pathway. In MM cells, apoptosis is also con-
trolled by the UPR pathway [32]. We therefore investi-
gated the possible effects of cyclin D1 on the signaling
associated with this pathway.
Cyclin D1 deregulates the pro- and anti-apoptotic balance
of the UPR after drug treatment
ER stress upregulates the UPR via three distinct ER-
resident proteins: activating transcription factor 6 (ATF6),
protein kinase R (PKR)-like endoplasmic reticulum kinase
(PERK) and inositol-requiring enzyme 1 (IRE1). These pro-
teins activate different transcriptional and translational pro-
grams [33]. The accumulation of unfolded proteins in the
ER lumen leads to dissociation of the chaperones BiP (im-
munoglobulin binding protein or the 78 kDa glucose-
regulated protein) and, to some extent, Grp94 (94 kDa
glucose-regulated protein or HSP90B1), from IRE1, PERK
and ATF6, leading to the activation of these ER stress sen-
sors. In myeloma cells, the interplay between these pro-
teins determines the outcome of ER stress: survival or
death [33].
Activated IRE1 acts as an endoribonuclease, cleaving
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Figure 3 Cyclin D1 expression amplifies a caspase-dependent apoptosis. A. 8226- and LP1-derived clones were treated for 24 h with vehicle (Ctrl)
or bortezomib (Bort, 5 or 10 nM). Cell viability was quantified in MTT assays. The absorbance (OD at 490 nm) of each clone treated with the drug
is expressed relative to that of the corresponding clone treated with vehicle (defined as 1 in arbitrary unit, AU). For each set of culture conditions,
the mean of triplicate ratios is indicated on the graph, together with the SD. ** p < 0.01. B. GFP- (in black) or D1-GFP-expressing clones (in gray)
were treated with vehicle (Ctrl) or 10 nM bortezomib. After 24 h, the cells were stained with anti-APO2.7 Ab and analyzed by flow cytometry.
At least 2 × 104 events were gated for each clone and set of culture conditions. Representative profiles of APO2.7-stained cells are shown. The
quantification of APO2.7-positive cells in several independent experiments is reported in the Additional file 3. C. Cells were treated with the
pancaspase inhibitor the Q-VD-OPh (or vehicle) for 1 h before treatment with bortezomib (or vehicle) at the concentrations indicated for an
additional 24 h. Cell viability was measured as described in A. Each experiment was carried out two or three times, in triplicate. ** p < 0.01. D.
Cells were treated as described above for 24 h. Whole-cell protein extracts were obtained and separated by SDS-PAGE. Proteins were blotted and analyzed
with the Abs indicated. The GAPDH Ab was used as a loading control. The proforms of caspase (Casp.) are indicated by gray arrows; the cleaved, activated
forms of caspase are indicated by black arrows. Cleaved PARP is indicated by a dotted arrow. E. The cells were treated as described above for 24 h. Whole-
cell protein extracts were prepared and separated by SDS-PAGE. Proteins were blotted and analyzed with the Abs indicated. The GAPDH Ab was used as a
loading control. MCL1 protein is indicated by an arrow.
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myeloma cells survival [34]. The blockade of IRE1 endo-
nuclease activity is associated with cell death [35]. GFP-
and D1-GFP-expressing clones from the two HMCLs
were treated with various concentrations of bortezomib,
which induces the UPR [36]. Whole-cell proteins ex-
tracts were then obtained and analyzed by western blot-
ting. Consistent with published data for MM patients
[35], XBP1s was found to be present in the two HMCLs,
whereas its levels were decreased by the ER stress im-
posed by bortezomib treatment (Figure 4A). In both
HCMLs, cyclin D1 expression accelerated the disappear-
ance of XBP1s. We concluded that cyclin D1 blocks the
survival-promoting XBP1-mediated UPR pathway.
The PERK/eukaryotic initiation factor 2 α (eIF2α)/ATF4
axis may protect cells or trigger cell death [32]. PERK acti-
vation leads to the phosphorylation of eIF2α, the activation
of ATF4, and the transcription of genes encoding ER chap-
erones and other targets [33]. The phosphorylated form ofFigure 4 Cyclin D1 expression impairs the IRE1 and PERKS pro-apoptotic a
clones were treated with vehicle (Cont) or treated with 5 or 10 nM bortezo
were prepared and analyzed by SDS-PAGE and in Immunoblotting with an
for charge and transfer. The experiments were carried out two times; one is pr
form is denoted “u”; the cleaved form of eIF2α is indicated by an arrow.eIF2α (p-eIF2α) was present in all HCMLs (Figure 4B),
consistent with constitutive activation of the PERK/eIF2α
signaling pathway. Following bortezomib treatment, eIF2α
was cleaved in a dose-dependent manner in cyclin D1-
GFP-expressing cells, but not in GFP-expressing cells, sug-
gesting that it was targeted by proteases (possibly caspases).
Overall, cyclin D1 expression impaired UPR-mediated sur-
vival programs.
CHOP is targeted by cyclin D1 to signal cell death
Each of the three sensors of the UPR simultaneously
activates pro- and anti-apoptotic signals [37]. For ex-
ample, PERK release and oligomerization lead to eIF2α
phosphorylation, resulting in the downregulation of
translation; a prosurvival mechanism. However, activa-
tion of the PERK/eIF2α/ATF4 axis leads to transcrip-
tion of the downstream target gene CHOP and, in turn,
to the transcription of effectors driving mitochondria-
dependent and -independent apoptosis [38]. CCAAT/xes of the UPR after bortezomib treatment. 8226- and LP1-derived
mib for 24 h. The cells were then harvested, and whole-cell proteins
ti-XBP1 (A) or EIF2α (B) Abs. The anti-β-actin Ab was used as a control
esented. The spliced and active form of XBP1 is denoted “s”, the unspliced
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CHOP (also known as GADD153) is the executioner
molecule in ER-mediated apoptosis. There is crosstalk
between the PERK and ATF6 sensor systems and the
signaling pathways for both these systems converge in
the activation of CHOP transcription [33]. Total RNA
was purified from HCMLs after bortezomib treatment
and analyzed by RT-quantitative PCR. The Fc values
obtained indicated that cyclin D1 expression signifi-
cantly increased the expression of CHOP (Figure 5A).
These data suggest that a specific CHOP-mediated ER
stress response was initiated by the presence of cyclin
D1 in bortezomib-treated cells. By contrast, the ex-
pression of BiP and GRP94, downstream from PERK
activation, was affected in different ways in different
HCMLs (Figure 5B). Caspase 4 is the recognized ER-
specific executioner caspase [37]. The activating cleav-
age of caspase 4 was enhanced in cyclin D1-expressing
cells (Figure 5C). Moreover, prior treatment of the cells
with the caspase 4 inhibitor Z-LEVD partially restored
cell viability in D1-GFP-expressing clones (Figure 5D).
We concluded that a cell death program induced by the UPRFigure 5 Cyclin D1 activates the UPR pro-apoptotic pathway after bortezo
vehicle (control) for 24 h. The expression of the CHOP (A), BiP and GRP94 (B
mean of triplicate samples is presented, together with the SD. All experime
treated as described above. Proteins were blotted on membranes and p
a loading control. D. Cells were treated with a caspase 4 inhibitor (Z-LE
8226 or 10 nM LP1, respectively) for another 24 h. Cell viability was estiand mediated by the transcription factor CHOP was ampli-
fied by cyclin D1 in bortezomib-treatedHCMLs.
Our data demonstrate that cyclin D1 expression favors a
pro-apoptotic UPR pathway, increasing the sensitization of
HMCLs to bortezomib.
Discussion
MM is relatively homogeneous in terms of its histological,
clinical and biologic properties, but it is characterized by
genetic and phenotypic complexities with implications for
treatments. Gene expression profiling assays have con-
firmed that MM patients from the CD-1/2 group (MM ex-
pressing cyclin D1) have a better prognosis than those from
the MS and MF groups (MM expressing cyclin D2) [17].
We investigated the molecular basis of this behavior, by ex-
pressing cyclin D1 in HMCLs belonging to groups of MM
patients with a poor prognosis. We studied the 8226 and
LP1 cell lines because they produce little or no cyclin D1.
The constitutive expression of cyclin D1 is cytotoxic in B
cells [24]. We therefore obtained cell clones producing only
moderate to low levels of cyclin D1. Nevertheless, cyclin
D1 expression was found to be associated with higher levelsmib treatment. Cells were treated with bortezomib (B, 5 or 10 nM) or
) genes was determined by RT quantitative-PCR. For each series, the
nts were carried out three times. *p < 0.05, **p < 0.01. C. Cells were
robed with an anti-caspase 4 Ab. The anti-GAPDH Ab was used as
VD, 1 μM) for 1 h, and then with vehicle or bortezomib (7.5 nM for
mated in MTT assays. *p < 0.05.
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previously reported [16,28]. These observations are consist-
ent with previous reports that MM of the CD-1/2 group re-
spond rapidly to treatment, and that their response rates
are high. However, the duration of complete responses has
been shown to be shorter for this group of tumors than for
other types of MM [39], possibly due to the higher rates of
proliferation of cyclin D1-expressing tumor cells.
Comparison of the transcriptional profiles of 8226 and LP1
with and without cyclin D1 expression showed that many
genes were up- or down-regulated in the presence of cyclin
D1. However, only a small number of genes were coordi-
nately regulated by cyclin D1 in both cell types (Additional
file 4). We then focused on the cell functions controlled by
cyclin D1. The genes differentially expressed in both cell
types were enriched in genes associated with apoptosis/cell
death and inflammation. We then investigated the potential
mechanism by which cyclin D1 might modulate the apop-
totic response.
Cyclin D1 expression significantly increased the apop-
tosis of 8226 and LP1 cells after a bortezomib treatment.
This finding is consistent with those obtained by Kuroda
et al. for RPMI 8226 cells [28] and indicates that the ex-
pression of cyclin D1 amplifies the response when the
apoptotic machinery is activated.
We found that cyclin D1 affected at least two of the
three branches of UPR and enhanced an ER stress-
induced apoptosis, regardless of genetic background of
the HMCL. Plasma cells are terminally differentiated B
lymphocytes that secrete immunoglobulins and have a
high demand for protein synthesis and exocytosis [40].
The survival of MM cells is highly dependent on the
UPR, and inefficient or prolonged UPR activation gener-
ates ER stress that can signal apoptosis [41,42]. In MM
cells, the three arms of the ER stress program are acti-
vated, but the CHOP response is limited. Moreover, MM
cells can increase the ER stress response further, with
ATF4 and ATF6 coordinately inducing CHOP transcrip-
tion. This causes a shift in the ER stress from a protect-
ive to a destructive mechanism. Bortezomib, a potent
antimyeloma compound, takes advantage of this prop-
erty and upregulates PERK activity [36]. In the cell
models we developed, cyclin D1 expression disrupted
the UPR balance, favoring death and amplifying the ef-
fects of bortezomib on the PERK/CHOP axis.
The mechanism by which cyclin D1 modifies the
UPR has not yet been determined. ATP, Ca2+ and an
oxidizing environment are required for correct protein
folding [43]. We previously reported that cyclin D1 in-
hibits mitochondrial activity in B-cell lymphoma, by
competing with hexokinase 2 for binding to the voltage-
dependent anion channel [10]. Cyclin D1 binding modifies
the flux of ATP/ADP/Pi metabolites, with a potentially
major impact on protein synthesis and folding. Furtherexperiments are required to confirm this hypothesis in our
cell models.
Pro- and antiapoptotic members of the BCL2 family
are crucial regulators of apoptosis in plasma cells. Sev-
eral studies have demonstrated that BCL2 and MCL1
are essential for the survival of plasma cell survival
[44,45]. Consistent with these findings, BCL2 and MCL1
levels rapidly decrease in cyclin D1-expressing cells (i.e.
in cells programmed for death). The MCL1 and BCL2
proteins regulate the apoptotic pathway mediated by
mitochondria, but they are also involved in ER stress-
mediated apoptosis. Indeed, chemical treatments or
changes in the microenvironment lead to severe ER
stress, initiating apoptosis. This process is mediated by
the induction of CHOP, which eliminates BCL2, thereby
counteracting the anti-apoptotic function of this protein
[37]. It has recently been shown, in MM cells, that the
UPR and, more specifically, the PERK-eIF2α-ATF4
branch of this pathway, regulates MCL1 levels [46,47].
Thus, both the apoptotic and UPR pathways are in-
volved in the degradation of BCL2 and MCL1. We found
that caspase activation was correlated with the decrease
in BCL2 and MCL1 levels after bortezomib-treatment.
Bortezomib inhibits the proteasome, so the degradation
of BCL2 and MCL1 may be essentially due to caspase-
mediated cleavage, as previously suggested [48-50], ra-
ther than degradation by the proteasome [51]. This
would be consistent with a master role for caspases in
the downregulation of BCL2 and MCL1 after bortezo-
mib treatment.
Conclusion
We report here that cyclin D1-expressing MM cells are
particularly sensitive to ER-stress and the UPR. Our re-
sults suggest that drugs targeting UPR effectors may act
in synergy with bortezomib, sensitizing MM cells with a
poor prognosis to bortezomib and improving the clinical
response of patients.
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